

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bell *et al.*

Confirmation No.: 4773

Appl. No. 09/664,444

Art Unit: 1645

Filed: September 18, 2000

Examiner: R. Zeman

For: **ONCOLYTIC VIRUS**

Atty. Docket: 18003

Cust. No. 31976

**Information Disclosure Statement Under 37 C.F.R. § 1.97(b)(4)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on accompanying Form PTO/SB/08a be considered by the Examiner and made of record.

Disclosure of patents and other written materials

Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made or that information more material to the examination of the present patent application does not exist and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

Filing of this Information Disclosure Statement

This Information Disclosure Statement is being filed concurrently with a request for continued examination under 37 C.F.R. § 1.114. Therefore, no statement or fee is required. The USPTO is hereby authorized to charge any fee deficiency required to prevent abandonment of the current application or credit any overpayment to Deposit Account 50-1677.

Applicants respectfully request that the listed documents be made of record in the present case. It is respectfully requested that the Examiner initial and return a copy of the accompanying Form PTO/SB/08a and indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,

/Douglas A. Golightly/  
Douglas A. Golightly  
Agent for Applicants  
Registration No. 51,244  
240-631-2500 ext. 3342

Date: August 2, 2007